Suppr超能文献

中心体靶向酪氨酸激酶活性并不能增强慢性骨髓增殖性疾病的致癌性。

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.

机构信息

Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, DKFZ and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

出版信息

Leukemia. 2012 Apr;26(4):728-35. doi: 10.1038/leu.2011.283. Epub 2011 Oct 21.

Abstract

Constitutive tyrosine kinase activation by reciprocal chromosomal translocation is a common pathogenetic mechanism in chronic myeloproliferative disorders. Since centrosomal proteins have been recurrently identified as translocation partners of tyrosine kinases FGFR1, JAK2, PDGFRα and PDGFRβ in these diseases, a role for the centrosome in oncogenic transformation has been hypothesized. In this study, we addressed the functional role of centrosomally targeted tyrosine kinase activity. First, centrosomal localization was not routinely found for all chimeric fusion proteins tested. Second, targeting of tyrosine kinases to the centrosome by creating artificial chimeric fusion kinases with the centrosomal targeting domain of AKAP450 failed to enhance the oncogenic transforming potential in both Ba/F3 and U2OS cells, although phospho-tyrosine-mediated signal transduction pathways were initiated at the centrosome. We conclude that the centrosomal localization of constitutively activated tyrosine kinases does not contribute to disease pathogenesis in chronic myeloproliferative disorders.

摘要

通过相互染色体易位导致的组成型酪氨酸激酶激活是慢性骨髓增殖性疾病的一种常见发病机制。由于中心体蛋白已被反复鉴定为 FGFR1、JAK2、PDGFRα 和 PDGFRβ 酪氨酸激酶的易位伙伴,因此假设中心体在致癌转化中起作用。在这项研究中,我们研究了靶向中心体的酪氨酸激酶活性的功能作用。首先,并非所有测试的嵌合融合蛋白都常规发现中心体定位。其次,通过用 AKAP450 的中心体靶向结构域创建人工嵌合融合激酶将酪氨酸激酶靶向到中心体,虽然磷酸酪氨酸介导的信号转导途径在中心体处起始,但未能增强 Ba/F3 和 U2OS 细胞的致癌转化潜力。我们得出结论,组成型激活的酪氨酸激酶的中心体定位不会导致慢性骨髓增殖性疾病的发病机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验